Gavin Marx
Overview
Explore the profile of Gavin Marx including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1063
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Itchins M, Liang S, Brown C, Barnes T, Marx G, Chin V, et al.
JTO Clin Res Rep
. 2024 Sep;
5(9):100703.
PMID: 39309618
Introduction: ALK-positive lung cancers represent a molecularly diverse disease. With drug exposure, driving selection pressure, and resistance pathways, disease relapse will emerge. There is compelling rationale to investigate novel treatment...
2.
Grimison P, Mersiades A, Kirby A, Tognela A, Olver I, Morton R, et al.
J Clin Oncol
. 2024 Aug;
42(34):4040-4050.
PMID: 39151115
Purpose: The aim of this randomized, placebo-controlled, two-stage, phase II/III trial was to determine the efficacy of an oral cannabis extract in adults with refractory nausea and/or vomiting during moderately...
3.
Li T, Timmins H, Mahfouz F, Trinh T, Mizrahi D, Horvath L, et al.
JAMA Netw Open
. 2024 Aug;
7(8):e2424139.
PMID: 39120903
Importance: Chemotherapy-induced peripheral neuropathy (CIPN) is a substantial adverse effect of anticancer treatments. As such, the assessment of CIPN remains critically important in both research and clinic settings. Objective: To...
4.
Narayanan S, Ngui N, Kinchington B, Choi J, Hughes T, Rutovitz J, et al.
Cancer Med
. 2024 Jun;
13(12):e7325.
PMID: 38899493
Aim: There has been significant progress made in developing novel targeted therapies in the neoadjuvant setting for non-metastatic HER2-positive breast cancer, which may be used in combination with conventional chemotherapy...
5.
Howdle G, Stephanou A, Barrett J, Roushdy S, Ngui N, Hughes M, et al.
ANZ J Surg
. 2024 May;
94(9):1539-1544.
PMID: 38747551
Background: The suspension of breast cancer screening during the COVID-19 pandemic altered patient diagnosis and management. This study investigates the impact of the COVID-19 lockdowns, screening delays and reduced healthcare...
6.
Marx G, Chowdhury S, Krieger L, Hovey E, Shapiro J, Tran B, et al.
Asia Pac J Clin Oncol
. 2024 Apr;
20(4):435-443.
PMID: 38639402
Studies of patients with castrate-resistant prostate cancer at high risk of developing overt metastases but with no current evidence of evaluable disease on computed tomography or bone scan non-metastatic castrate-resistant...
7.
Mahon K, Sutherland S, Lin H, Stockler M, Gurney H, Mallesara G, et al.
Prostate
. 2024 Mar;
84(8):747-755.
PMID: 38544345
Background: Elevated circulating growth differentiation factor (GDF15/MIC-1), interleukin 4 (IL4), and IL6 levels were associated with resistance to docetaxel in an exploratory cohort of men with metastatic castration-resistant prostate cancer...
8.
Mahfouz F, Li T, Timmins H, Horvath L, Harrison M, Grimison P, et al.
J Natl Compr Canc Netw
. 2024 Feb;
22(2):108-116.
PMID: 38364373
Background: Chemotherapy-induced peripheral neurotoxicity (CIPN) affects the quality of life of cancer survivors. However, the impact of pain on symptom burden remains undefined. This study aimed to define differences in...
9.
Mahfouz F, Li T, Joda M, Harrison M, Horvath L, Grimison P, et al.
Support Care Cancer
. 2023 Dec;
32(1):46.
PMID: 38117349
Purpose: Sleep problems are commonly reported by cancer survivors; however, knowledge of the impact of chemotherapy-induced peripheral neurotoxicity (CIPN) on sleep quality remains limited. In this study, we explored the...
10.
Ganju V, Marx G, Pattison S, Amaro-Mugridge N, Zhao J, Williams B, et al.
Clin Cancer Res
. 2023 Nov;
30(2):304-314.
PMID: 37976042
Purpose: We assessed the safety and efficacy of an EGFR-targeted, super-cytotoxic drug, PNU-159682-packaged nanocells with α-galactosyl ceramide-packaged nanocells (E-EDV-D682/GC) in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had exhausted...